Progress of apatinib in the treatment of advanced gastric cancer

doi:10.12092/j.issn.1009-2501.2019.10.017

Abstract

Abstract:

Gastric cancer is one of the most common malignant tumors in the world. Early diagnosis is difficult and most patients have missed the best timing of surgery when diagnosed. Therefore, systemic comprehensive therapy should be the best treatment option for advanced gastric cancer. Recent years, the standard chemotherapy regimen, such as platinum and fluorouracil-based regimen has been proven poor efficacy. However, with continuous research and development, the role of targeted drugs has become increasingly important in the treatment of advanced gastric cancer. Apatinib is a small molecule inhibitor of vascular endothelial growth factor (VEGF) receptor developed and applied in China, which highly selectively competes with the binding site of adenosine triphosphate (ATP) of VEGF-2 in cells, inhibits the formation of new blood vessels in tumor tissues, and then inhibits the occurrence and development of tumor tissues. This article systematically reviewed the current research status and progress of apatinib in the treatment of advanced gastric cancer in order to provide a reference for further clinical application.

Key words: gastric cancer, apatinib, vascular endothelial growth factor, targeted therapy

CLC Number:

R453.9

JING Qindong, LIU Haipeng, WANG Binru, CHEN Kang, CHEN Xiao. Progress of apatinib in the treatment of advanced gastric cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1194-1200.

References

［1］Bray F, Ren JS, Masuyer E, et al. Global estimates of cancer prevalence for 27 sites in the adult population in 2008［J］. Int j Cancer, 2013, 132(5):1133-1145.
［2］Liu Y, Zhang X, Chen L, et al. Cancer incidence and mortality in Gansu province, 2012［J］, Chin J Cancer Res，2016, 28(3):301-310.
［3］Shan F, Miao R, Xue K, et al. Controlling angiogenesis in gastric cancer: A systematic review of anti-angiogenic trials［J］. Cancer Lett, 2016, 380(2):598-607.
［4］Kerbel RS. Tumor angiogenesis［J］. N Engl J Med,358(19):2039-2049.
［5］Ferrara N, Gerber HP, LeCouter J, The biology of VEGF and its receptors［J］. Nat Med,2003,(9):669-676.
［6］Dvorak HF, Brown LF, Detmar M, Dvorak AM, Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis［J］. Am J Pathol,1995,146(5):1029-1039.
［7］秦叔逵,李进.阿帕替尼治疗胃癌的临床应用专家共识［J］.临床肿瘤学杂志, 2015,20(9):841-847.
［8］National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology: Gastric cancer (Version 2. 2015)［EB /OL］. 2015［2015-08-10］. http:// www. nccn. org/professionals/physiciangls/pdf/gastric.pdf.
［9］Paul C, Luisa IA, Liguang L, et al. VEGFr inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29［C］. Proc Amer Assoc Cancer Res,2006, 47:1746.
［10］陈淑慧,阳帆帆,何君,等.胃癌靶向治疗研究最新进展［J］.中国临床药理学与治疗学,2015,20(8):950-955.
［11］Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis［J］. J Clin Oncol, 2005,23(5):1011-1027.
［12］Holmes K, Roberts OL, Thomas AM, et al. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition［J］. Cell Signal, 2007,19(10):2003-2012.
［13］Tian S, Quan H, Xie C,et al.YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor‐2 tyrosine kinase with potent activity in vitro and in vivo［J］.Cancer Science,2011,102(7):1374-1380.
［14］陈祖华,张朦琦,高静,等.阿帕替尼治疗小鼠人源化胃癌移植瘤模型的疗效观察及CD31的意义［J］.基础医学与临床,2018,38(12):1696-1701.
［15］Li J,Zhao X,Chen L,et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies［J］.BMC Cancer,2010,5(10):529.
［16］Li J, Qin S, Xu J, et al. A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma［C］//全国临床肿瘤学大会暨年csco. 2011.
［17］Li J, Qin S, Xu J, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction［J］.J Clin Oncol,2016, 34(13):1448-1454.
［18］胡刚,阿帕替尼治疗晚期胃癌疗效分析［J］.内蒙古医学杂志,2018,50(2):142-144.
［19］刘朝敏,王少龙,姜鹤群,等.阿帕替尼对二线化疗失败的晚期胃癌患者预后的影响［J］.成都医学院学报,2018,13(2):158-161,177.
［20］樊翠珍,张晓静,初玉平,等.阿帕替尼治疗化疗失败的进展期胃癌的疗效及安全性［J］.肿瘤,2018,38(4):356-361.
［21］郎丰平,赵毓毅,范鹏.甲磺酸阿帕替尼治疗晚期胃癌的疗效及安全性分析［J］.实用癌症杂志,2017,32(6):996-998.
［22］Zhang Y,Gou M,Han C,et al.Efficacy and safety of apatinib as second-line therapy for advanced gastric cancer:a single-center observational study［J］.Anticancer Drugs,2017,5.DOI:10.1097/CAD.0000000000000582.
［23］黄毅超,刘云军,何宛谦,等.阿帕替尼与替吉奥联合治疗晚期胃癌疗效分析及对相关细胞因子的影响［J］.中国中西医结合消化杂志,2018,26(3):252-255.
［24］吴志伟,蔡俊,陆网坤,等.阿帕替尼联合替吉奥二线治疗晚期胃癌的临床观察［J］.中国当代医药,2017,24(23):69-75.
［25］杨欣怡,李宁,邓文英,等.阿帕替尼联合替吉奥与阿帕替尼二线治疗晚期胃癌的临床疗效比较［J］.肿瘤基础与临床,2017,30(6):483-486.
［26］Wang Y, Bi M, Zhang H, et al. Apatinib in gastric carcinoma: A case report of partial response for first-line treatment in advanced disease［J］. Asia Pac J Clin Oncol,2017,13(5):e528-e530.
［27］Yang Y, Zhang W, Yao J, et al. First-line treatment of apatinib in elderly patient of advanced gastric carcinoma: A case report of NGS-driven targeted therapy［J］. Cancer Biol Ther, 2018,19(5):355-358.
［28］樊鑫鑫,吕慧芳,陈贝贝,等.替吉奥联合阿帕替尼一线治疗晚期胃癌的临床效果观察并文献复习［J］.中国医学前沿杂志,2017,9(2):63-67.
［29］Zhang H.Apatinib for molecular targeted therapy in tumor［J］.Drug Des Devel Ther,2015,13(9):6075-6081.
［30］段洪瑞,宋岩,姜晓艳.阿帕替尼联合FOLFOX化疗方案治疗晚期胃癌的疗效观察［J］.中国实用医药,2017,12(28):155-157.
［31］田春艳,尹进波,许丰铭,等.阿帕替尼联合免疫调节剂治疗晚期胃癌的效果观察［J］.浙江医学,2018,40(9):996-997.
［32］赵鑫.阿帕替尼联合紫杉醇治疗晚期化疗耐药HER-2阴性胃癌的临床效果评价［J］.中外医疗,2017,36(35):127-129.
［33］宋朝阳.肿节风注射液联合阿帕替尼治疗晚期胃癌的临床研究［J］.现代药物与临床,2017,32(6):1114-1117.
［34］Zhang Y, Han C, Li J, et al. Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study［J］. Sci Rep, 2017, 7(1):13208.
［35］Lee HJ, Moon JY, Baek SW. Is treatment-emergent toxicity a biomarker of efficacy of Apatinib in gastric cancer［J］ ? J Clin Oncol, 2016, 34(31):3823.
［36］Liu X, Qin S, Wang Z, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study［J］. J Hematol Oncol, 2017,10(1):153.
［37］Chen Z, Huang W, Tian T, et al. Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer［J］. J Hematol Oncol,2018,11(1):20.
［38］Zhang S. Problematic analysis and inadequate toxicity data in phase III apatinib trial in gastric cancer［J］.J Clin Oncol, 2016, 34(31):3821.
［39］Fornaro L, Vasile E, Falcone A. Apatinib in advanced gastric cancer: A doubtful step forward［J］. J Clin Oncol,2016,34(31):3822-3823.
［40］Chen HD, Zhou J, Wen F, et al. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer［J］.J Cancer Res Clin Oncol,2017,143(2):361-368.

[1]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[2]	LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui. Advances in targeted therapy for HER2-positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
[3]	XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua. Research progress of biomarkers related to the efficacy of HER2 positive breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
[4]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[5]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[6]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[7]	LIU Le, QI Wenbo, BAI Yuping, LIU Qian, YIN Zhenyu, LI Xiaomei, YU Yang, CHEN Hao. Influencing factors of PD-1/PD-L1 immune checkpoint inhibitor immunotherapy for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 95-101.
[8]	CHEN Wenjie, WANG Yabing, CHEN Xiaolin, REN Junling, ZHAO Wanjun, CHEN bin. Advances in the study of iodine-resistant differentiated thyroid cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 116-120.
[9]	LIU Chen, FANG Mengdie, XU Hao, LI Chao, REN Juan, ZUO Bowen, ZHANG Yanmei. Atractyloside targets the area of action of oncoprotein BORIS to inhibit cancer cell proliferation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1005-1013.
[10]	LU Ruibin, ZHAO Hui, XIE Qiuling, HU Lu, GUO Chaowan, PEI Yunlin, XIONG Sheng. Anti-FGF-2 nanobody inhibits rat corneal angiogenesis induced by alkali burn [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 609-615.
[11]	JIANG Yuhua, ZHI Hui, LU Linming, TIAN Dahao, WANG Xiaoqing, GE Yu, XIE Shangfu, WANG Qi. AHVAC-I reverses tumor growth of cancer-associated fibroblasats in gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 389-394.
[12]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[13]	WU Yi, ZHU Akao, SHAN Yuqiang, YING Rongchao, JIN Huicheng. Resveratrol regulates miR-409-3p/FKBP14 to inhibit the malignant biological processes of gastric cancer BGC823 cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 968-975.
[14]	YANG Shitao, ZHU Yihong, TANG Wenxin. Effects of aripiprazole combined with duloxetine on the treatment effect and VEGF level in patients with refractory depression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 937-942.
[15]	TIAN Dahao, LU Linming, ZHI Hui, ZHOU Jue, WANG Xiaoqing, JIANG Yuhua. AHVAC-I inhibits the proliferation in human primary gastric cancer cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 505-511.